Catheter Precision, Inc. Q1 2026 Financial Report: Key Highlights and Investor Insights
Overview
Catheter Precision, Inc. (Commission File No. 001-38677) has released its quarterly report for the period ended March 31, 2026. This article summarizes the key financial, operational, and corporate developments disclosed in the report, focusing on information relevant to shareholders and potential investors.
Key Points from the Quarterly Report
- Corporate Information: The company is headquartered at 1670 Highway 160 West, Suite 205, Fort Mill, SC 29708. It was formerly known as Ra Medical Systems, Inc.
- Share Capital Structure:
- Common Stock: Authorized shares stand at 500,000,000, with 2,692,473 issued and outstanding as of March 31, 2026, compared to 1,738,955 at December 31, 2025. This represents a significant increase in issued shares during the quarter.
- Preferred Stock: Multiple series authorized:
- Series B: 3,000 authorized; 1,632 issued/outstanding (down from 2,229 at year-end)
- Series C1: 3,687 authorized; 3,470 issued/outstanding (up from 0 at year-end)
- Series J: 9,490 authorized; 9,490 issued/outstanding (unchanged)
- Series X: 15,404 authorized; 0 issued/outstanding
- Par Value: All shares have a par value of \$0.0001 per share.
- Segment Reporting:
- The company reports two segments, including Cardiac Electrophysiology and Private Aviation, reflecting diversification beyond its traditional business lines.
- Major Customers: The company identified three major customers during the quarter, indicating customer concentration risk.
- Profit and Loss:
- The report shows a loss of \$4,045,000 for the quarter ended March 31, 2025, under retained earnings, with no material profit recorded for preferred stock, common stock, or additional paid-in capital.
- Business Acquisitions:
- Acquisition of Flyte business segment is reported, with explicit mention of Cardiac Electrophysiology as a segment and Flyte as a newly acquired business. This could be a strategic move expanding the company’s addressable market and product offerings.
- Private Placements and PIPE Financings:
- Several private placements and PIPE financings were completed during 2025 and early 2026, resulting in issuance of new preferred shares and warrants. These capital raises have implications on dilution and future cash flows.
- Warrants and Convertible Securities:
- The company has multiple classes of warrants and convertible notes, some of which are antidilutive and excluded from computation of earnings per share. This suggests potential future dilution if exercised or converted.
- Subsequent Events:
- Post quarter-end, the company issued Series D Preferred Stock (April 20, 2026) and Series C2 Convertible Preferred Stock (April 21, 2026) in conjunction with securities purchase agreements. These subsequent capital raises may materially affect share values and company cash position.
- Segment Operating Expenses:
- Other segment items include consulting fees, investor relations, SEC fees, insurance, and other selling, general, and administrative expenses, primarily travel, IT, and rent. These non-core expenses may impact margins.
- Fair Value Measurements:
- No material fair value adjustments or recurring basis liabilities were reported for the quarter.
Shareholder Alerts & Price Sensitive Information
- Significant Share Issuance: The jump in common shares outstanding from 1.7M to 2.7M within one quarter represents substantial dilution. Investors should monitor how these additional shares impact earnings per share and market capitalization.
- Preferred Stock and Convertible Issuances: The introduction and issuance of Series C1 and Series D preferred shares, as well as new PIPE financings, suggest aggressive capital raising. Such activity typically signals either growth initiatives or liquidity needs and may pressure share prices if not offset by revenue growth.
- Business Diversification: The acquisition of Flyte and expansion into Private Aviation segment are strategic moves that could change the company’s risk and return profile. Investors should assess the synergies and risks associated with these new segments.
- Customer Concentration: Reliance on three major customers increases revenue risk. Any changes in these relationships could quickly affect financial performance.
- Subsequent Events: The post-quarter capital raises and securities purchase agreements are potentially price sensitive, especially if they alter the company’s liquidity, ownership structure, or strategic direction.
- Antidilutive Securities: The presence of antidilutive warrants and convertible notes means further dilution could occur in the future, affecting existing shareholders’ interests.
Conclusion
Catheter Precision, Inc.’s Q1 2026 report reveals a company in transition, aggressively raising capital, expanding business segments, and issuing new shares. Investors should closely monitor dilution, customer concentration, post-quarter financing activities, and the integration of new business lines. These developments are likely to impact share price, either positively (if growth and synergies are realized) or negatively (if dilution and expenses outweigh new revenues).
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Investors should review official filings and consult with professional advisors before making investment decisions. The information summarized herein is based on available disclosures and may be subject to change.
